Skip to main content

Table 4 Comparison of BMI, HbA1c, FPG, Basal and Bolus Insulin Doses at Baseline and 26 weeks after IDeg Treatment among patients who were previously on insulin Glargine (Group A) vs. previously insulin naïve (Group B)

From: Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population

Characteristics Baseline 26 weeks
BMI (SDS)
 Group A (n = 20) −0.11 ± 0.76 0.04 ± 0.73
 Group B (n = 10) 0.38 ± 1.31 0.37 ± 1.19
HbA1c (%)
 Group A (n = 20) 8.50 ± 0.65 8.16 ± 0.67*
 Group B (n = 10) 11.94 ± 1.78 9.47 ± 2.52*
FPG (mg/dL)
 Group A (n = 20) 135.80 ± 19.05 104.50 ± 20.69*
 Group B (n = 10) 199.20 ± 45.18 119.10 ± 39.50*
Insulin dose (U/kg of body weight/day)
 Basal insulin
  Group A (n = 20) 0.45 ± 0.15 0.47 ± 0.14
  Group B (n = 10) 0.36 ± 0.05 0.43 ± 0.13
 Bolus insulin
  Group A (n = 20) 0.46 ± 0.20 0.32 ± 0.10*
  Group B (n = 10) 0.54 ± 0.22 0.41 ± 0.21
 Total insulin
  Group A (n = 20) 0.91 ± 0.33 0.79 ± 0.21*
  Group B (n = 10) 0.91 ± 0.24 0.84 ± 0.31
  1. BMI = body mass index; FPG = fasting plasma glucose; HbA1c = glycated hemoglobin, SDS = Standard Deviation Score
  2. *P < 0.05 versus baseline (paired t-test)
\